Literature DB >> 33465371

Protective Functions of ZO-2/Tjp2 Expressed in Hepatocytes and Cholangiocytes Against Liver Injury and Cholestasis.

Jianliang Xu1, P Jaya Kausalya1, Noémi Van Hul2, Matias J Caldez2, Shiyi Xu1, Alicia Ghia Min Ong1, Wan Lu Woo1, Safiah Mohamed Ali1, Philipp Kaldis3, Walter Hunziker4.   

Abstract

BACKGROUND & AIMS: Liver tight junctions (TJs) establish tissue barriers that isolate bile from the blood circulation. TJP2/ZO-2-inactivating mutations cause progressive cholestatic liver disease in humans. Because the underlying mechanisms remain elusive, we characterized mice with liver-specific inactivation of Tjp2.
METHODS: Tjp2 was deleted in hepatocytes, cholangiocytes, or both. Effects on the liver were assessed by biochemical analyses of plasma, liver, and bile and by electron microscopy, histology, and immunostaining. TJ barrier permeability was evaluated using fluorescein isothiocyanate-dextran (4 kDa). Cholic acid (CA) diet was used to assess susceptibility to liver injury.
RESULTS: Liver-specific deletion of Tjp2 resulted in lower Cldn1 protein levels, minor changes to the TJ, dilated canaliculi, lower microvilli density, and aberrant radixin and bile salt export pump (BSEP) distribution, without an overt increase in TJ permeability. Hepatic Tjp2-defcient mice presented with mild progressive cholestasis with lower expression levels of bile acid transporter Abcb11/Bsep and detoxification enzyme Cyp2b10. A CA diet tolerated by control mice caused severe cholestasis and liver necrosis in Tjp2-deficient animals. 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene ameliorated CA-induced injury by enhancing Cyp2b10 expression, and ursodeoxycholic acid provided partial improvement. Inactivating Tjp2 separately in hepatocytes or cholangiocytes showed only mild CA-induced liver injury.
CONCLUSION: Tjp2 is required for normal cortical distribution of radixin, canalicular volume regulation, and microvilli density. Its inactivation deregulated expression of Cldn1 and key bile acid transporters and detoxification enzymes. The mice provide a novel animal model for cholestatic liver disease caused by TJP2-inactivating mutations in humans.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bile-Blood Barrier; Constitutive Androstane Receptor; Human Disease; Tight Junction Protein-2; Zonula Occludens-2

Year:  2021        PMID: 33465371     DOI: 10.1053/j.gastro.2021.01.027

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  3 in total

1.  ZO-2 favors Hippo signaling, and its re-expression in the steatotic liver by AMPK restores junctional sealing.

Authors:  Laura González-González; Helios Gallego-Gutiérrez; Dolores Martin-Tapia; José Everardo Avelino-Cruz; Christian Hernández-Guzmán; Sergio Israel Rangel-Guerrero; Luis Marat Alvarez-Salas; Erika Garay; Bibiana Chávez-Munguía; María Concepción Gutiérrez-Ruiz; Dinorah Hernández-Melchor; Esther López-Bayghen; Lorenza González-Mariscal
Journal:  Tissue Barriers       Date:  2021-10-23

2.  Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency.

Authors:  Chao Zheng Li; Hiromi Ogawa; Soon Seng Ng; Xindi Chen; Eriko Kishimoto; Kokoro Sakabe; Aiko Fukami; Yueh-Chiang Hu; Christopher N Mayhew; Jennifer Hellmann; Alexander Miethke; Nahrin L Tasnova; Samuel J I Blackford; Zu Ming Tang; Adam M Syanda; Liang Ma; Fang Xiao; Melissa Sambrotta; Oliver Tavabie; Filipa Soares; Oliver Baker; Davide Danovi; Hisamitsu Hayashi; Richard J Thompson; S Tamir Rashid; Akihiro Asai
Journal:  JHEP Rep       Date:  2022-02-01

3.  ZO-2/Tjp2 suppresses Yap and Wwtr1/Taz-mediated hepatocyte to cholangiocyte transdifferentiation in the mouse liver.

Authors:  Jianliang Xu; P Jaya Kausalya; Alicia Ghia Min Ong; Christine Meng Fan Goh; Safiah Mohamed Ali; Walter Hunziker
Journal:  NPJ Regen Med       Date:  2022-09-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.